Kaizer

Kezar Life Sciences is a clinical-stage biotechnology company headquartered in South San Francisco, California, dedicated to developing novel small molecule therapeutics for immune-mediated diseases and cancer. The company's research focuses on two primary areas: the inhibition of the immunoproteasome and the modulation of the Sec61 translocon, a key channel for protein secretion and transmembrane protein insertion. Kezar's lead candidate, zetomipzomib (KZR-616), is a selective immunoproteasome inhibitor being evaluated in Phase 2 trials for conditions such as lupus nephritis and autoimmune hepatitis. Additionally, the company is advancing KZR-261, a first-in-class Sec61 translocon inhibitor, through early-stage clinical development for the treatment of various solid tumors. By targeting these fundamental cellular pathways, Kezar aims to provide transformative treatments for patients with limited therapeutic options.